NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Vancouver, British Columbia – TheNewswire - March 16, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announces that pursuant to its ongoing collaboration with Clearmind Medicine Inc. (“ Clearmind ”), a patent application has been filed by Clearmind with the Intellectual Property Department  in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD).   This innovative treatment combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera.